Eve Dias participates with a poster to EHA2024




In her poster, Eve Días presents her work on on the impact of STAG2 mutations in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Her study investigates how these mutations confer a clonal advantage to leukemic cells and alter their response to microenvironmental signals. Utilizing CRISPR/Cas9 technology, the research examines cellular parameters, transcriptomic data, and genetic dependencies, aiming to identify potential therapeutic targets.

The findings highlight the role of STAG2 mutations in disease progression and offer insights into new treatment strategies for MDS and AML.

For more information, follow the link: EHA Library – The official digital education library of European Hematology Association (EHA) (ehaweb.org)